Among these CTAs: DKKL1, FBXO39, and OIP5 have emerged as particularly attractive targets for immunotherapy due to their specific overexpression in tumor tissues and roles in promoting oncogenesis. This evidence concerns the gene DKKL1 and neoplasm.